Celecoxib Treatment for Lung Cancer
- Registration Number
- NCT00108186
- Lead Sponsor
- US Department of Veterans Affairs
- Brief Summary
This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Pathologically confirmed and surgically resectable non small cell lung cancer and subjects must be ineligible for or refuse, neoadjuvant therapy
Exclusion Criteria
Hypersensitivity to celecoxib or NSAIDs, previous history of GI bleeding or ulceration, chronic or concurrent use of steroids and renal insufficiency
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Arm 1 Celecoxib Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
- Primary Outcome Measures
Name Time Method Measure bio-markers; safety measures 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
VA Greater Los Angeles Healthcare System, West LA
🇺🇸West Los Angeles, California, United States